<DOC>
	<DOCNO>NCT01075971</DOCNO>
	<brief_summary>This multi-center , open-label , preference study two sublingual formulation buprenorphine HCl , opioid-dependent patient buprenorphine maintenance therapy . The objective study evaluate overall preference two buprenorphine sublingual formulation , switch market tablet ( Subutex® ) new fast dissolving tablet ( FDT ) , opioid-dependent patient buprenorphine 8 mg 16 mg daily maintenance therapy .</brief_summary>
	<brief_title>Study Two Formulations Buprenorphine HCl Opioid-dependent Subjects Buprenorphine Maintenance Therapy ( Study P04451 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Patients must demonstrate willingness participate study comply procedure sign write informed consent . Patients must least ( ≥ ) 18 year age , either sex . Patients treat opioid dependence Subutex® , stable dosage 8 mg 16 mg daily , respect legal drug attachment . Patients must understand able adhere dose visit schedule , agree report concomitant medication / product adverse event investigator designee . Women childbearing potential ( include woman less one year postmenopausal woman become sexually active ) must use agree use acceptable method birth control ( e.g. , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterile ( e.g. , hysterectomy tubal ligation ) . Women childbearing potential counseled appropriate use birth control study . Women currently sexually active must agree consent use one abovementioned method become sexually active participate study . Women childbearing potential must urine pregnancy test negative result within 2 week prior inclusion ( perform control investigator designee ) . Patients refuse take daily dose study medication control center . Patients unable complete evaluation . Women pregnant nursing . Patients history hypersensitivity buprenorphine hydrochloride excipient one formulation . Patients current evidence alcohol abuse . Patients severe respiratory dysfunction , severe hepatic dysfunction , acute alcohol intoxication delirium tremens . Initiation increase dose , within past 7 day schedule study , treatment : benzodiazepine , depressant central nervous system : morphine derivative ( analgesic , antitussive ) , certain antidepressive agent , sedative H1 antihistamine , barbiturate , benzodiazepine , anxiolytic benzodiazepine , neuroleptic , clonidine clonidinelike agent , monoamine oxydase [ MAO ] inhibitor . Patients current evidence clinically significant hematopoietic , metabolic , cardiovascular , immunologic , neurologic , hematological , gastrointestinal , hepatic , renal , psychiatric , cerebrovascular , respiratory disease , disorder , judgment investigator , may interfere study evaluation affect patient safety . Patients used investigational product within 30 day prior enrollment . Patients participate another trial time . Patients intend donate blood study within 3 month study completion . Patients exclusion period `` Fichier National de personnes qui se prêtent à de recherches biomédicales sans bénéfice individuel direct '' ( National Index person participate biomedical research without direct individual benefit , National Index volunteer ) . Patients without Social Security number , whose maximum annual compensation ( 3,800 € ) exceed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Buprenorphine tablet</keyword>
	<keyword>Fast dissolving tablet</keyword>
	<keyword>Opioid dependant patient</keyword>
</DOC>